Clinical Trial Update: EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating EMD 525797 in combination with cetuximab and irinotecan in KRAS wild-type metastatic colorectal cancer has completed enrollment. Resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Cetuximab (cetuximab)
• EMD 525797
• Irinotecan (Irinotecan)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Metastatic Colorectal Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2016-03-30